読み込み中
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
前日終値
$11.00
+$0.14 · +1.29%
日中の時刻はETです。市場データは遅延する場合があります。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日中レンジ
現在 $11.00
52週レンジ
現在 $11.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
35
割高
センチメント
65
強気
リスク
36
中程度のリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日中レンジ
現在 $11.00
52週レンジ
現在 $11.00
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 9.7万 USD | — | — | — | — |
| 粗利益 | −9.7万 USD | — | — | — | — |
| 研究開発 | 4661.6万 USD | 1433.6万 USD | 1541.1万 USD | 2621.4万 USD | 2332.2万 USD |
| 販売・一般管理 | 2117万 USD | 1602.5万 USD | 2486.4万 USD | 1892.1万 USD | 1235万 USD |
| 営業費用 | 6778.6万 USD | 8202万 USD | 4027.5万 USD | 4513.5万 USD | 3567.2万 USD |
| 受取利息 | 832.3万 USD | 813.2万 USD | 462万 USD | 137.5万 USD | — |
| 減価償却費と償却費 | 9.7万 USD | — | — | — | — |
| 営業利益 | −6788.3万 USD | −8202万 USD | −4027.5万 USD | −4513.5万 USD | −3567.2万 USD |
| 純利益 | −5985.1万 USD | −7389.7万 USD | −3511.9万 USD | −4524.4万 USD | −4748万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$27.17
上昇余地（147.00%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1876.46万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1184.54万0.12%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1059.3万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF414.05万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO278.41万0.02%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA228.61万0.01%218.24億 USD0.03%$32.79+0.40%
Dimensional - US Small Cap ETFDFAS191.35万0.01%338.69億 USD0.31%$78.35+0.32%
Fidelity Fundamental Small-Mid Cap ETFFFSM187.79万0.12%14.4億 USD0.43%$34.13+0.62%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASFidelity Fundamental Small-Mid Cap ETFFFSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
